In ICC, one patient with MDS with excess blasts 2 (MDS-EB2) and one patient with t-MDS, according to the 2016 WHO criteria, were reclassified into the MDS/AML group, and four patients with MDS-EB2 were reclassified into MDS/AML with MR gene mutations. This evidence concerns the gene NR3C2 and acute myeloid leukemia.